Introduction to Leukemia Part 2

68問 • 2023-12-01
MAHATHIR ALPHA
通報

問題

- Acute megakaryoblastic leukemia - This is a rare disorder characterized by extensive proliferation of megakaryoblasts, atypical megakaryocytes and thrombocytopenia

解答

問題

What are the 2 goals in the treatment if Leukemias

解答

問題

What are the four general types of theraphy for leukemias?

解答

問題

A combination of drugs is usually used in this theraphy

解答

問題

It stimulate the patients own immune system to mount a response against the malignant cells

解答

問題

An example of these are Rituxin

解答

問題

Fill in the Blanks: Blast cut-off for a diagnosis of AML WHO- ____ FAB- ____

解答

問題

AML with blasts 20 - 30 % by WHO can benefit from therapies for ________________ that were approved by USFDA

解答

問題

Small, monomorphic

解答

問題

Large, heterogenous

解答

Introduction to Leukemia Part 2

暗記メーカー

得点

0 / 10

正答率

0%

正解: 0

不正解: 0

未解答: 10

 
ankimaker.com

問題一覧

  • 1

    - Acute megakaryoblastic leukemia - This is a rare disorder characterized by extensive proliferation of megakaryoblasts, atypical megakaryocytes and thrombocytopenia

    M7

  • 2

    What are the 2 goals in the treatment if Leukemias

    Eradicate the leukemic cell mass, Give supportive care

  • 3

    What are the four general types of theraphy for leukemias?

    Chemotherapy, Bone marrow transplant, Radiotheraphy, Immunotheraphy, Monoclonal antibodies

  • 4

    A combination of drugs is usually used in this theraphy

    Chemotheraphy

  • 5

    It stimulate the patients own immune system to mount a response against the malignant cells

    Immunotheraphy

  • 6

    An example of these are Rituxin

    Monoclonal antibodies

  • 7

    Fill in the Blanks: Blast cut-off for a diagnosis of AML WHO- ____ FAB- ____

    20%, 30%

  • 8

    AML with blasts 20 - 30 % by WHO can benefit from therapies for ________________ that were approved by USFDA

    MYELODYSPASIA

  • 9

    Small, monomorphic

    L1

  • 10

    Large, heterogenous

    L2

  • 11

    Burkitt-cell type

    L3

  • 12

    Minimally differentiated

    M0

  • 13

    Without maturation

    M1

  • 14

    With maturation

    M2

  • 15

    Hypergranular promyelocytic

    M3

  • 16

    Myelomonocytic

    M4

  • 17

    (a) monoblastic, (b) monocytic

    M5

  • 18

    Erythroleukemia

    M6

  • 19

    Megakaryoblastic

    M7

  • 20

    Undifferentiated blasts, AML-not otherwise categorized

    M0 myeloid

  • 21

    Blasts and promyelocytes predominate without further maturation of myeloid cells

    M1 myeloid

  • 22

    Myeloid cells demonstrate maturation beyond the blast and promyelocyte stage

    M2 myeloid

  • 23

    Promyelocytes predominate in the bone marrow

    M3 myelomonocyte

  • 24

    Both myeloid and monocytic cells are present to the extent of at least 20% of the total leukocytes

    M4 myelomonoctyic

  • 25

    Most cells are monocytic; two subtypes (a and b) are recognized, one characterized by large blasts in bone marrow and peripheral blood, the other (differentiated type) by monoblasts, promonocytes, and monocytes

    M5 monocytic

  • 26

    Also known as Di Guglielmo syndrome; abnormal proliferation of both erythroid and granulocytic precursors; may include abnormal megakaryocytic and monocytic proliferations

    M6 erythroleukemia

  • 27

    Large and small megakaryoblasts with a high nuclear- cytoplasmic ratio; pale, agranular cytoplasm

    M7 megakaryocytic

  • 28

    One population of cells within the case; small cells predominant; nuclear shape is regular with an occasional cleft; chromatin pattern is homogeneous and nucleoli are rarely visible; cytoplasm is moderately basophilic

    L1 homogenous

  • 29

    Large cells with an irregular nuclear shape; clefts in the nucleus are common; one or more large nucleoli are visible; cytoplasm varies in color

    L2 heterogenous

  • 30

    Cells are large and homogeneous in size; nuclear shape is round or oval; one to three prominent nucleoli; cytoplasm is deeply basophilic with vacuoles often prominent

    L3 Burkitt lymphoma type

  • 31

    Try to familliarize!

    .

  • 32

    Try to familliarize!

    .

  • 33

    Try to familliarize!

    .

  • 34

    Try to familliarize!

    .

  • 35

    Try to familliarize!

    .

  • 36

    Try to familliarize!

    .

  • 37

    There is an increase in both erythroblasts and myeloblasts

    Erythroleukemia

  • 38

    They may possibly cause myeloblastic leukemia

    M1, M2 or M4

  • 39

    3 sequentially morphological defined phases

    Preponderance of abnormal erythroblasts, Erythroleukemia, Myeloblastic leukemia

  • 40

    Erythroleukemia

    M6

  • 41

    -This is rare and is characterized by a bone marrow having a predominance of erythroblast -It has three sequentially morphologically defined phases -Anemia is common

    M6

  • 42

    -Acute monoblastic leukemia - >80% of the nonerythroid cells in the bone marrow are monocytic -There is extensive infiltration of the gums, CNS, lymph nodes and extramedullary sites

    M5

  • 43

    This type of M5 is well differentiated (<80% monoblasts)

    M5B

  • 44

    This type of M5 is poorly differentiated (>80% monoblasts)

    M5A

  • 45

    M5 is further divided into:

    M5A, M5B

  • 46

    -Acute myelomonoblastic leukemia -Both myeloblasts and monoblasts are seen in the bone marrow and peripheral blood -Infiltration of extramedullary sites is more common than with the pure granulocytic variants

    M4

  • 47

    -Hypogranular promyelocytic -The bone marrow has > 30% blasts -The WBC count is increased. -Like the M3 type, treatment causes a release of the granules and may send the patient into disseminated intravascular coagulation and subsequent bleeding and -It is characterized by a 15,17 translocation

    M3m

  • 48

    M3m is characterized by what?

    15,17 chromosomal translocation

  • 49

    M3 is characterized by what?

    15,17 chromosomal translocation

  • 50

    M2 is characterized by what?

    8,21 chromosomal translocation

  • 51

    What does the treatment of M3 causes?

    Treatment causes a release of the granules and may send the patient into disseminated intravascular coagulation and subsequent bleeding

  • 52

    -Hypergranular promyelocytic -This form of AML has a bone marrow with >30% blasts -Is more virulent than other forms -Occurs with a medium age of 39 -The WBC count is decreased -Treatment causes a release of the granules and may send the patient into disseminated intravascular coagulation and subsequent bleeding -It is characterized by a 15,17 chromosomal translocation

    M3

  • 53

    -Myeloblastic with maturation -The bone marrow shows 30-89% blasts and > 10% promyelocytes; -This is characterized by an 8,21 chromosomal translocation -This occurs in older adults

    M2

  • 54

    - Myeloblastic without maturation - The bone marrow shows >90% blasts and < 10% promyelocytes -The disease occurs in older adults

    M1

  • 55

    What are the different classifications of Acute myeloid leukemia ?

    M1, M2, M3, M3m, M4, M5, M6, M7

  • 56

    The classification of Acute myeloid leukemia depends on this factors

    Bone marrow blast morphology, Degree of cell maturation, Cytochemical stains, Immunophenotyping

  • 57

    What is the other term for Acute myeloid leukemia?

    Acute granulocyte leukemia

  • 58

    It is a rare trilineage leukemia

    B/T lymphoid/myeloid

  • 59

    Acute leukemias with mixed lineage(binotypic/phenotypes for two different lineages)

    B lymphoid/myeloid, T lymphoid/myeloid, B/T lymphoid, Myeloid/Natural killer, B/T lymphoid/myeloid

  • 60

    •It is more common in males •It has a poorer prognosis than any of the B cell ALLs which have a cure rate of 70%

    T cell ALL

  • 61

    True/False: If the WBC count is < 10 x 109/L at presentation, the prognosis is good; If the WBC count is > 20 x 109/L at presentation the prognosis is poor.

    True

  • 62

    Patients younger then 1 and greater than 13 have a _______________.

    poor prognosis

  • 63

    What are the most important prognostic indicators?

    Age, WBC counts, Cell type

  • 64

    Clinical findings of ALL

    Pancytopenia with resulting fatigue, pallor, fever, weight loss, irritability, anorexia, infection, bleeding, and bone pain.

  • 65

    Where does L2 occurs?

    In adults

  • 66

    Absence of any leukemia related signs and symptoms and return of bone marrow and peripheral blood values to within normal value

    Complete remission

  • 67

    Infiltration of extramedullary sites are common

    M4

  • 68

    Extensive infiltration of the gums, CNS....

    M5